News
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
The diabetes and obesity care markets are under disruption. Glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have catapulted in popularity.
The thing
IMTS 2024: Oerlikon Unveils Innovations in Surface Solutions and Latest PVD Equipment in Live Virtual Reality
Oerlikon, a leading provider of surface technology and additive manufacturing solutions, is pleased to announce its participation at the IMTS 2024 exhibitions. Oerlikon will showcase its broad
Julius Baer Group Ltd. to redeem Perpetual Tier 1 Subordinated Bonds issued 12 September 2017 on first call date
Here's Why Eli Lilly Stock Dropped 12% Last Month
Shares of Eli Lilly (NYSE: LLY) fell 20% in July, according to data from S&P Global Market Intelligence. The pharmaceutical stock tumbled after one of the company's competitors announced promising
Severe thunderstorms drive insured losses to USD 60 billion in first half of 2024, Swiss Re Institute estimates
Ad hoc announcement pursuant to Art. 53 LR News Release
Swiss Re announces Group CFO succession as John Dacey retires in 2025
AEVIS VICTORIA SA (AEVS:SW) achieved revenues of more than CHF 450 million in the first half-year 2024
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
When a major player announces good news in a lucrative market like weight loss drugs, it's often enough to drive shares of competitors down based on the assumption that they will have struggles
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and
Presentation of the 2024 half-year results of the Julius Baer Group
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar
Julius Baer appoints Stefan Bollinger as Chief Executive Officer
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
Watch out, Novo Nordisk and Eli Lilly. Per some new clinical-trial data it published on July 17, the massive Swiss pharmaceutical company Roche Holding (OTC: RHHBY) might have a winning weight-loss
The Kudelski Group signs agreement to sell SKIDATA to ASSA ABLOY
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q2 2024 Earnings CallJul 18, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than
Solid demand; record-high Operational EBITA margin
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996.
But
David Chétrit appointed as CEO of Kudelski Security
Robust economies set to drive insurance growth and profitability, says Swiss Re Institute
Holcim acquires Mark Desmedt to accelerate circular construction as a driver of profitable growth